Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04417088 · ClinicalTrials.gov registry record · Phase 1
Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy
A Phase 1 study, sponsored by InSightec.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT04417088 is a Phase 1 study that has completed, run by InSightec. The registered enrollment target is 28 participants.
The verdict
NCT04417088, a Phase 1 study, has completed, sponsored by InSightec.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and feasibility of the Exablate Model 4000 Type 2 system when used as a tool to open the blood-brain-barrier (BBB) in subjects with recurrent glioblastoma (rGBM) undergoing carboplatin monotherapy.
Interventions
- DRUG Carboplatin
- DEVICE Exablate BBBD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2020-11-06 |
| Est. Completion | 2023-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04417088
The ClinicalTrials.gov registry entry for NCT04417088 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is InSightec, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Carboplatin is the first listed.
NCT04417088 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04417088 about?
NCT04417088 is a clinical study titled "Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy". The purpose of this study is to evaluate the safety and feasibility of the Exablate Model 4000 Type 2 system when used as a tool to open the blood-brain-barrier (BBB) in subjects with recurrent glioblastoma (rGBM) undergoing carboplatin monotherapy.
What is the current status of trial NCT04417088?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2020-11-06. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT04417088?
The interventions under investigation include: Carboplatin (DRUG), Exablate BBBD (DEVICE).
Who is sponsoring clinical trial NCT04417088?
This trial is sponsored by InSightec, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.